Keywords: Merck & Co, Vytorin, IMPROVE-IT trial continuation, Pfizer, Zithromax, Irregular heart rhythm, USA, FDA

Merck & Co gets all clear to continue Vytorin study; FDA warns on Pfizer's Zithromax

Article | 13 March 2013

Print This

US pharma giant Merck & Co (NYSE: MRK) said yesterday that the Data Safety Monitoring Board (DSMB) of the IMPROVE-IT ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in